|
According to the
most recent scientific research, aging
individuals afflicted with
rheumatoid arthritis are at
60% great-er risk
of dying from heart disease
than the general population.1 The
vascular damage seen in rheumatoid
individuals appears to be an accelerated
form of atherosclerosis.2
Similar analysis
shows that over time, rheumatoid
arthritis sufferers also sustain damage
to the eyes, lungs, and
skin.3-6
The common factor
linking rheumatoid arthritis to these
potentially deadly conditions is
system-wide, chronic
inflammation in the body. The same
systemic inflammatory events, especially
those involving the potent cytokine
known as TNF-alpha, contribute to
atherosclerosis even in people who don’t
have rheumatoid arthritis7—and
that’s why we all need to pay special
attention to limiting inflammatory
changes throughout our lifetime.
Until recently,
mainstream medicine’s focus on highly
profitable single-target drugs (like
Enbrel®) has left the 1.3 million
rheumatoid arthritis sufferers in this
country with few attractive options.
While effective at controlling symptoms,
these drugs are expensive and produce
potentially life-threatening side
effects associated with chronic
suppression of immunity, such as serious
infections and certain cancers.8-10
Fortunately, a novel
set of multi-targeted natural
agents has been identified that can
disrupt the inflammatory
cascade involved in
rheumatoid arthritis at many stages.
These agents have also been shown to
reduce joint pain, stiffness, and
deterioration of cartilage.
In this article, you
will learn about the latest research on
curcuminoids and
andrographolides—natural
compounds shown to specifically target
the painful conditions associated with
rheumatoid arthritis and the underlying
genetic and biochemical factors that
cause rheumatoid inflammation.
formof
curcumin which early evidence shows
may be as effective in alleviating the
symptoms of rheumatoid arthritis as the
non-steroidal anti-inflammatory (NSAID)
drug diclofenac! Animal studies already
demonstrate that curcumin relieves pain
comparably to diclofenac, so this is an
exciting and evolving field of research.11
Rheumatoid
Arthritis—Inflammation Run Amok
While its causes are
not fully understood, researchers have
long known that rheumatoid arthritis
(RA) is an autoimmune
disorder.
An optimally
functioning immune system remains on
constant alert, patrolling for invading
microbes and emerging cancer cells. When
launched into action, various
immunomodulating agents—including
the cell-signaling proteins known as
cytokines—provoke an inflammatory
response in the body. In healthy
individuals, the immune system keeps
this inflammatory response under
control to prevent
injury to the body itself.12
For the unfortunate
individuals stricken with rheumatoid
arthritis, this balance is disrupted—the
body mistakes some of its own tissue as
“foreign,” resulting in a chronic
inflammatory response. The immune system
attacks the delicate
synovial membranes that
line the joints, producing pain,
swelling, bone loss, and overgrowth of
the membranes themselves. Eventually
joints stiffen, limiting range of
motion, accompanied by progressively
worsening pain and a severe decline in
quality of life.13
RA is one of a
growing handful of diseases in which
experts have recognized the central role
of an inflammatory cytokine
called tumor necrosis
factor-alpha (TNF-alpha)—the
“master regulator” of inflammation in
many systems of the body. These
conditions—which include
psoriasis and
inflammatory bowel disease—are
collectively known as “TNF
Related Chronic
Inflammatory Diseases,”
or TRECID.14
Mainstream medical
research remains largely focused on
various drugs that block
TNF-alpha as a way to try to stop the
damage involved in TRECID diseases.15
Though TNF-blockers like golimumab,
infliximab, and adalimumab
can be effective, there are some
individuals for whom these interventions
provide little or no relief.16-18
TNF-blockers can also be extremely
expensive, requiring painful periodic
injections, with an array of side
effects, some of which may paradoxically
exacerbate autoimmune disease.18-20
Another main class
of pharmaceutical interventions for RA,
known as disease-modifying
anti-rheumatic drugs (DMARDs), include
methotrexate, cyclosporine, and cytoxan.21
These drugs are often less costly, but
generally no better in terms of efficacy
and side effect profile.22,23
The truth is that
tolerable, safe treatment of RA
continues to elude pharmaceutical
solutions—in large part because they are
single-target
therapies focused on a limited number
(usually just one) of the underlying
mechanisms behind RA. The powerful
disruption of the immune system by those
drugs often produces a comprehensive
state of immune deficiency that opens
the patient to potentially disastrous
infections—the FDA has recently issued
“Black Box” warnings for some of the
biological agents in this class.10
A novel set of
low-cost, natural compounds have emerged
that specifically attack the
inflammation associated with rheumatoid
arthritis at multiple points in the
inflammatory process. Together they
provide the potential for
multi-targeted relief,
both “upstream” within the inflammatory
cascade—at earlier stages than
TNF-blocking drugs—and “downstream,” at
later stages than traditional
anti-rheumatic drugs (DMARDs).
Andrographis:
A Multi-Modal Inflammation Fighter
Over the past 25
years, extracts of the Asian herb
Andrographis paniculata
have aroused considerable scientific
interest owing to their apparent power
to favorably modify immune
system function.24-26
Its bioactive components, called
andrographolides,27
are well absorbed after oral
dosing28
and have been extensively tested as
anti-inflammatory agents.29
Unlike the
single-targeted action of TNF-blockers
and anti-rheumatic drugs,
andrographolides stimulate beneficial
activity at multiple points in the
inflammatory process, providing mutually
reinforcing effects.29
Andrographolides
inhibit activity of the
pro-inflammatory compound known as
inducible nitric oxide synthase
(iNOS). This helps exert a powerful
anti-inflammatory
effect.30
Readers who are familiar with the
vascular benefits of eNOS (endothelial
NOS) should note that, unlike eNOS,
iNOS is pro-inflammatory and often
involved in disease states, where it is
desirable to inhibit its actions.
Andrographolides
suppress production of the
pro-inflammatory cytokines TNF-alpha and
prostaglandin E2 (PGE-2),
preventing their gene expression at
multiple levels.31,32
By doing so they downregulate the
chemical signaling pathways that cells
use to “tell” each other to initiate the
inflammatory response that plays a key
role in rheumatoid arthritis.33
Scientific analysis
has further revealed that
andrographolides operate “upstream”
within the process of the inflammatory
cascade by blocking the effects of the
pro-inflammatory
transcription factor nuclear
factor-kappaB (NF-kB).34
NF-kB is found in
almost all human cells. It plays a key
role in cellular responses to stress,
cytokines, free radicals, oxidized
low-density lipoprotein (LDL), and
bacterial or viral pathogens.
Accordingly, its central role as a
first-responder to oxidative damage,
infection, and toxin-induced stress
links it to inflammation, cancer, and
chronic disease.35
NF-kB tightly regulates virtually all
factors downstream in the inflammatory
cascade, including cytokines known as
interleukins, hormones known as
prostaglandins, and
TNF-alpha.
By blocking NF-kB,
andrographolides inhibit production of a
host of inflammatory mediators in one
simple step.36
Just as critically, they permit
normal activity of vital immune
surveillance cells as they
simultaneously suppress
over-active inflammatory cells, as
demonstrated in animal studies.37
This is a critical
feature that distinguishes
andrographolides from most
anti-rheumatic drugs (DMARDS). While
andrographolides suppress inflammatory
immune factors,36
DMARDs can suppress immune function in
general, resulting in an
increased risk of infection.38
Andrographolides
also act as powerful
antioxidants, limiting the
number of free radicals thrown off by
inflammatory cells and reducing overall
inflammation and pain in animal studies.39-43
Clinical
Breakthroughs in Natural Arthritis
Relief
In 2005, a group of
researchers led by Dr. Raphael A. Burgos
at the Universidad Austral in Valdivia,
Chile, began publishing seminal work on
the properties of a select formulation
of andrographolides in
countering the effects of rheumatoid
arthritis.
Burgos’s group
discovered that the formulation
suppressed inflammatory mediators such
as interferon-gamma and interleuklin-2
(IL-2), while protecting against cell
death induced by corticosteroids.44
They further demonstrated that
andrographolides directly prevent NF-kB
from binding to DNA in inflammatory
cells, thereby preventing it from
activating production of dangerous
inflammatory mediators.45
In 2009, Burgos’s
team was able to demonstrate this
andrographolide formulation’s dramatic
anti-rheumatic effects for the first
time in humans.
Just 200 mg
daily for 18 weeks resolved RA-related
anemia, restoring red blood cell levels
to the normal range while lowering
the inflammatory marker
C-reactive protein (CRP) to
normal.46
When rheumatoid
arthritis sufferers were given 200 mg of
andrographolides or the same dose of a
non-steroidal anti-inflammatory drug
(NSAID), the patients receiving the
andrographolides had a significant drop
in RA-specific auto-antibodies
(antibodies directed against their own
tissue), while the NSAID group saw a
rise in some of those levels.47
Relief from joint pain and rigidity was
seen in the andrographolide and the
NSAID groups.
... Scientific advances in our
understanding of curcumin’s
molecular action have led to its
application in the treatment of
rheumatoid arthritis.
After these two
preliminary, unpublished studies
validated the efficacy of
andrographolides, Dr. Burgos’s group
subsequently performed a larger study: a
prospective, randomized, double blind,
placebo-controlled clinical trial. They
published the results in late 2009.48
Significant improvements over placebo
were found for joint pain
and swelling as well as the number and
severity of tender, swollen
joints. Quality of life scores
also improved significantly in the
supplemented subjects, and levels of
some biochemical markers of immune
system activation were decreased in the
group who took the active supplement.
Optimal
Arthritis Control
|
|
• Rheumatoid arthritis is an
autoimmune disorder
characterized by chronic
inflammation.
• Safe, multi-targeted
natural agents have been
identified that disrupt the
inflammatory cascade involved in
rheumatoid arthritis at multiple
stages—and reduce joint
swelling, pain, and stiffness.
• Andrographolides from the
Asian herb Andrographis
paniculata and curcuminoids from
turmeric have multi-targeted,
complementary actions that
powerfully counter the
inflammatory response.
• They work by suppressing
pro-inflammatory cytokines,
modulating the immune response,
favorably modulating gene
expression, and neutralizing
free radicals.
• A clinical study published
in 2009 showed that a select
andrographolide formulation
reduced joint pain and swelling
in patients with rheumatoid
arthritis.
• In 2009, a high-potency
formulation of curcumin
outperformed the non-steroidal
anti-inflammatory drug (NSAID)
diclofenac in an unpublished
human clinical trial.
|
|